(Q46592051)

23 December 2017

title

Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem (English)

1 reference

23 December 2017

1 reference

1 reference

1

Joseph L Kuti

1 reference

23 December 2017

David P Nicolau

series ordinal

4

object named as

David P Nicolau

1 reference

23 December 2017

author name string

Sheryl Horowitz

series ordinal

2

1 reference

23 December 2017

Charles H Nightingale

series ordinal

3

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

23 December 2017

published in

Pharmacotherapy

1 reference

23 December 2017

volume

25

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

page(s)

935-941

1 reference

23 December 2017

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacokinetics of ceftazidime in febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Intermittent bolus dosing of ceftazidime in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Interactions in vitro between agents used to treat melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacokinetics of meropenem in patients with intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Continuous infusion versus intermittent administration of meropenem in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.935

10.1592/PHCO.2005.25.7.935

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

release_4rkbyhkup5antbsydmatn55ivu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4rkbyhkup5antbsydmatn55ivu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

23 December 2017